All In Biotech

Drug Trial Radar · NCT06938321

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

An Open Label, Multicenter, Phase Ib/II Clinical Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Apr 30, 2025

Primary completion

May 2027

Study completion Dec 2027

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Apr 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK130 in combination with AK112 therapy for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced biliary tract cancer (BTC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial. 2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination with AK130 therapy or monotherapy in the treatment of advanced BTC.

Conditions

  • Biliary Tract Cancer

Interventions

  • AK112Drug

    Following a predefined dose and date.

  • AK130Drug

    Following a predefined dose and date.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with dose limiting toxicities (DLTs)Time frame: During the first three weeks.
  2. Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 30 days after the last dose of study drug or starting new anti-cancer therapy.
  3. Objective Response Rate (ORR) (Phase II)Time frame: Through study completion, an average of 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.